Skip to main content
. 2009 Jul 15;52(9):1755–1765. doi: 10.1007/s00125-009-1453-1

Table 2.

Baseline characteristics of the fixed cohort by insulin glargine exposure group: type 2 diabetic patients only (n = 19,899)

Characteristic Data presented as Non-glargine insulin Non-glargine plus glargine insulin Insulin glargine only p valuea
Subjects % (n) 92.7 (18,455) 5.2 (1,033) 2.1 (411)
Sex, % women % (n) 48.8 (8,996) 48.5 (501) 52.6 (216) 0.13
Age, years Median (LQ, UQ) 65 (56,72) 57 (49, 66) 69 (59,77) <0.0001
BMI, kg/m2 Mean (SD) 30.4 (6.1) 27.9 (5.7) 30.1 (6.2) <0.0001
Systolic BP, mmHg Mean (SD) 139.3 (22.2) 136.1 (19.5) 140.5 (20.5) 0.19
Diastolic BP, mmHg Mean (SD) 76 (12) 77 (12) 77 (13) 0.006
HbA1c, % Mean (SD) 8.5 (1.7) 9.0 (1.7) 9.3 (1.8) <0.0001
Duration of diabetes
 ≥5 years % (n) 83.2 (15,360) 76.8 (793) 75.2 (309) <0.0001
Prior Insulin
 ≥5 years on insulin % (n) 37.2 (6,867) 47.1 (487) 4.6 (19) <0.0001
Age at diagnosis, years Median 53 46 59 <0.0001
Prior cancer
 Ever % (n) 7.4 (1,357) 5.0 (52) 9.3 (38) 0.59
 ≤5 years ago % (n) 3.6 (664) 2.7 (28) 5.6 (23) 0.35
Any CVD % (n) 18.6 (3,441) 12.1 (125) 22.1 (91) 0.016
Ever smoked % (n) 29.9 (4,335) 28.4 (247) 24.8 (77) 0.001
Use of oral glucose-lowering drugs at baselineb % (n) 28.9 (4,559) 23.4 (169) 80.0 (295) <0.0001
On three or more oral glucose-lowering drugs at baseline % (n) 4.0 (745) 3.1 (32) 29.4 (121) <0.0001
In the two most deprived SIMD quintiles % (n) 47.1 (8,686) 35.4 (366) 54.0 (222) <0.0001

aAge- and sex-adjusted. Values are for tests of whether the overall variation between groups is significant and are taken from linear and logistic regressions of continuous and binary variables, respectively

bDenominator for oral glucose lowering drugs excludes 3,005 (15%) of subjects for whom oral drug prescription is not known with certainty

LQ, Lower quartile; UQ, upper quartile